51 completed. 51 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 51 | Completed 51 |
| Phase 2 | 8 | Completed 8 |
Follow Dwarfism: new trials by email Literature Review of Dwarfism trials Research Report on Dwarfism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day - Achondroplasia | Phase 3 | Completed | QED Therapeutics, a BridgeBio company | 114 | 2023-11-10 | 2026-03-17 |
| A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia Navepegritide (TransCon CNP), Placebo for Navepegritide (TransCon CNP) - Achondroplasia | Phase 2 / Phase 3 | Completed | Ascendis Pharma Growth Disorders A/S | 84 | 2023-03-03 | 2026-07-14 |
| A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency Lonapegsomatropin - Adult Growth Hormone Deficiency, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma Endocrinology Division A/S | 220 | 2021-12-16 | 2026-07-07 |
| A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is Macimorelin, Arginine, Clonidine - Growth Hormone Deficiency | Phase 3 | Completed | AEterna Zentaris | 101 | 2021-11-16 | 2024-08-12 |
| A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency Lonapegsomatropin, Placebo, Somatropin - Growth Hormone Deficiency, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma Endocrinology Division A/S | 264 | 2020-12-03 | 2026-07-07 |
| Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD Genotropin, somatrogon - Growth Hormone Deficiency | Phase 3 | Completed | Pfizer | 87 | 2019-02-07 | 2021-10-14 |
| Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children Y-shape pegylated somatropin, Norditropin®, Norditropin - Growth Hormone Deficiency | Phase 2 / Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 434 | 2018-12-26 | 2024-01-24 |
| A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial TransCon hGH - Growth Hormone Deficiency, Pediatric, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma A/S | 298 | 2017-12-19 | 2026-07-07 |
| Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency MOD-4023, Genotropin - Growth Hormone Deficiency | Phase 3 | Completed | OPKO Health, Inc. | 44 | 2017-12-07 | 2021-08-12 |
| A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency TransCon hGH - Growth Hormone Deficiency, Pediatric, Endocrine System Diseases | Phase 3 | Completed | Ascendis Pharma Endocrinology Division A/S | 146 | 2017-11-13 | 2026-07-07 |
| A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency somapacitan, Norditropin - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 3 | Completed | Novo Nordisk A/S | 62 | 2017-03-03 | 2020-11-23 |
| A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD) Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin - Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone) | Phase 3 | Completed | Ascendis Pharma Endocrinology Division A/S | 162 | 2016-12-13 | 2026-07-07 |
| A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia BMN 111, Placebo - Achondroplasia | Phase 3 | Completed | BioMarin Pharmaceutical | 121 | 2016-12-12 | 2022-03-02 |
| Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency Macimorelin, Insulin - Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | Completed | AEterna Zentaris | 157 | 2015-12-03 | 2018-04-10 |
| Long-Acting Growth Hormone in Children Compared to Daily rhGH Somavaratan, rhGH - Growth Disorders | Phase 3 | Completed | Versartis Inc. | 138 | 2015-08-26 | 2022-12-30 |
| A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency somapacitan, somatropin - Adult Growth Hormone Deficiency, Growth Hormone Disorder | Phase 3 | Completed | Novo Nordisk A/S | 92 | 2015-02-12 | 2020-07-09 |
| Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. somapacitan, somatropin, placebo - Growth Hormone Disorder, Adult Growth Hormone Deficiency | Phase 3 | Completed | Novo Nordisk A/S | 301 | 2014-10-31 | 2020-11-23 |
| A Clinical Study to Assess the Efficacy and Safety of DA-3002 DA-3002, Genotropin® - Turner's Syndrome | Phase 3 | Completed | Dong-A ST Co., Ltd. | 58 | 2013-02-01 | 2018-07-26 |
| Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects Genotropin Pen, MARK VII pen - Growth Hormone Deficiency | Phase 3 | Completed | Pfizer | 120 | 2010-08-01 | 2012-05-22 |
| Three Times Weekly (TIW) Growth Hormone Therapy in Children on Hemodialysis somatropin - Kidney Failure, Chronic, Renal Dialysis | Phase 3 | Completed | Nationwide Children's Hospital | 3 | 2010-07-01 | 2015-05-05 |
Showing 20 of 51. Sign in to see all of them.
Dwarfism, Pituitary (40) · Failure to Thrive (6) · Pituitary Diseases (6) · Endocrine System Diseases (5) · Achondroplasia (3) · Turner Syndrome (3) · Bone Diseases (2) · Genetic Diseases, Inborn (2) · Laron Syndrome (2) · Musculoskeletal Diseases (2) · Osteochondrodysplasias (2) · Bone Diseases, Developmental (1) · Diabetes Mellitus (1) · Growth Disorders (1)
Bone Diseases, Developmental (50) · Bone Diseases (49) · Musculoskeletal Diseases (49) · Endocrine System Diseases (45) · Brain Diseases (41) · Central Nervous System Diseases (41) · Hypothalamic Diseases (41) · Nervous System Diseases (41) · Bone Diseases, Endocrine (40) · Hypopituitarism (39) · Pituitary Diseases (35) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (10) · Pathological Conditions, Signs and Symptoms (9)
Human Growth Hormone (24) · Growth Hormone (9) · somapacitan (3) · Insulin-Like Growth Factor I (2) · lonapegsomatropin (2) · macimorelin (2) · mecasermin (2) · somatrogon (2) · Anastrozole (1) · Arginine (1) · Blood Specimen Collection (1) · Citrullination (1) · Ethinyl Estradiol (1) · Insulin (1) · MOD-4023 (1)
Novo Nordisk A/S (8) · Pfizer (6) · Ascendis Pharma Endocrinology Division A/S (4) · Eli Lilly and Company (4) · AEterna Zentaris (2) · Ipsen (2) · LG Life Sciences (2) · Ascendis Pharma A/S (1) · Ascendis Pharma Growth Disorders A/S (1) · BioMarin Pharmaceutical (1) · BioPartners GmbH (1) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Daewoong Pharmaceutical Co. LTD. (1) · Dong-A ST Co., Ltd. (1) · EMD Serono (1)
United States (22) · United Kingdom (12) · Australia (11) · France (11) · Germany (11) · Japan (11) · Italy (10) · Poland (9) · Spain (8) · Turkey (Türkiye) (8) · Romania (7) · Slovakia (7) · Ukraine (7) · Canada (6) · Armenia (5)
HJ Ji, PhD (2) · Aimee Shu, MD (1) · Annamaria Colao, MD, PhD (1) · Byung Kyu Suh, M.D., Ph.D. (1) · Chang Jong Kim, M.D., Ph.D. (1) · Charlotte Hoeybye, MD (1)
PMID 36380045, PMID 18395480, PMID 15784709, PMID 16757526, PMID 16840832, PMID 17192294, PMID 19001519, PMID 19066295, PMID 20484474, PMID 21118739, PMID 21619701, PMID 22924571, PMID 24748824, PMID 28566441, PMID 29029101, PMID 29860473, PMID 30339244, PMID 30910221, PMID 32022863, PMID 32603494, PMID 34272849, PMID 34431071, PMID 34893062, PMID 35428884, PMID 36034448, PMID 36994923, PMID 38649657, PMID 39305160, PMID 39740666, PMID 39906034, PMID 39991735, PMID 41183961, PMID 41247754, PMID 42144862, PMID 42370681
2004 (2), 2015 (2), 2018 (2), 2008 (1), 2014 (1), 2016 (1), 2017 (1)